Salud financiera de hoja de balance de Pasithea Therapeutics

Salud financiera controles de criterios 4/6

Pasithea Therapeutics tiene un patrimonio de los accionistas total de $17.8M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $18.6M y $824.0K respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$9.36m
Patrimonio	US$17.81m
Total pasivo	US$823.98k
Activos totales	US$18.64m

Actualizaciones recientes sobre salud financiera

We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Rate

Jul 21

Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation

Apr 06

Recent updates

We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Rate

Jul 21

Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation

Apr 06

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($9.8M) de KTTA superan a sus pasivos a corto plazo ($660.4K).

Pasivo a largo plazo: Los activos a corto plazo de KTTA ($9.8M) superan a sus pasivos a largo plazo ($163.6K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: KTTA está libre de deudas.

Reducción de la deuda: KTTA no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: KTTA tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: KTTA tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 45.3% cada año

Salud financiera de hoja de balance de Pasithea Therapeutics

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Pasithea Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Rate

Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation

Recent updates

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

New major risk - Financial position

Pasithea Therapeutics Corp. announced that it has received $5.000003 million in funding

Pasithea Therapeutics Corp. announced that it expects to receive $5.000003 million in funding

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

New minor risk - Share price stability

Pasithea Therapeutics Corp. Announces Completion of Enrollment and Initial Dosing of Cohort 2 Following Positive Safety Review Committee Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial

Pasithea Therapeutics Corp., Annual General Meeting, Jun 26, 2024

Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer Patients

New major risk - Financial position

Pasithea Therapeutics Corp. Selects PAS-003 Lead Development Candidate

Pasithea Therapeutics Corp., Annual General Meeting, Nov 29, 2023

High number of new and inexperienced directors

Pasithea Therapeutics Corp. Publishes Study in Proceedings of the National Academy of Sciences Related to its PAS-003 Drug Discovery Program

Pasithea Therapeutics Corp. (NasdaqCM:KTTA) announces an Equity Buyback for 5,700,000 shares, for $4 million.

New major risk - Share price stability

Lucy Scientific Discovery Inc. (NasdaqCM:LSDI) made a proposal to acquire Pasithea Therapeutics Corp. (NasdaqCM:KTTA) for $22.2 million.

Pasithea Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Concord IP2 Recommends Stockholders to Vote for Boardroom Change at Pasithea Therapeutics

Price target decreased to US$2.30

Less than half of directors are independent

Concord IP2 Ltd Files a Lawsuit Against the Directors of Pasithea Therapeutics Corp

Camac Partners Comments on Pasithea Therapeutics’ Acquisition of AlloMek Therapeutics

Pasithea Therapeutics Corp. (NasdaqCM:KTTA) acquired AlloMek Therapeutics, LLC from Integral Biosciences Private Limited, Innovation Pathways LLC, Shakti BioResearch LLC and others for $11.3 million.

Camac Partners LLC Sends a Letter to Pasithea Therapeutics Corp

Less than half of directors are independent

Pasithea Therapeutics Corp. Appoints Alfred J. Novak to Its Board of Directors

Pasithea Therapeutics Corp. Appoints Dr. Merit Cudkowicz to its Scientific Advisory Board

Camac Partners Provides Information to Shareholders of Pasithea Therapeutics

Camac Partners Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting

Pasithea Therapeutics Corp. Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis

Concord Investment Partners Ltd Urges Stockholders of Pasithea Therapeutics Corp to Call Special Meeting

Concord IP2 Ltd Nominates Candidates to the Board of Pasithea Therapeutics Corp

We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Rate

Concord IP2 Ltd Files Solicitation Statement to Call a Special Meeting of Stockholders of Pasithea Therapeutics Corp

Concord IP2 Ltd Provides Information to Shareholders of Pasithea Therapeutics Corp

Concord IP2 Ltd Sends a Letter to Pasithea Therapeutics Corp

Stanley Gloss, the Chief Financial Officer of Pasithea Therapeutics Corp., Passes Away

Concord IP2 Ltd Sends a Letter to Pasithea Therapeutics Corp

Pasithea Therapeutics Corp., Annual General Meeting, Jun 23, 2022

Less than half of directors are independent

Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation

Pasithea Therapeutics Appoints Daniel Weinberger to Its Scientific Advisory Board

Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple Sclerosis

Pasithea Therapeutics Corp. announced that it has received $30.38 million in funding

Pasithea Therapeutics Corp. announced that it expects to receive $30.38 million in funding

Pasithea Therapeutics Adds Esketamine Nasal Spray to Its Clinic Offerings in the U.K

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera